These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33408750)

  • 1. Cost per response analysis of repository corticotropin injection
    Wan GJ; Chopra I; Niewoehner J; Hunter SF
    Drugs Context; 2020; 9():. PubMed ID: 33408750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.
    Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.
    Nazareth T; Datar M; Yu TC
    Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).
    Gold LS; Suh K; Schepman PB; Damal K; Hansen RN
    Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.
    Knight T; Bond TC; Popelar B; Wang L; Niewoehner JW; Anastassopoulos K; Philbin M
    Clinicoecon Outcomes Res; 2017; 9():271-279. PubMed ID: 28553129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials.
    Costello J; Njue A; Lyall M; Heyes A; Mahler N; Philbin M; Nazareth T
    Degener Neurol Neuromuscul Dis; 2019; 9():55-78. PubMed ID: 31308790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.
    Bindra J; Chopra I; Niewoehner J; Panaccio M; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():349-358. PubMed ID: 33986603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
    Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
    CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis.
    Hayes K; Panaccio MP; Goel N; Fahim M
    Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis.
    Hua LH; Hersh CM; Morten P; Kusel J; Lin F; Cave J; Varga S; Herrera V; Ko JJ
    J Manag Care Spec Pharm; 2019 Apr; 25(4):490-498. PubMed ID: 30917079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis.
    Dashputre AA; Kamal KM; Pawar G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):666-676. PubMed ID: 28530523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M
    J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Burden of Multiple Sclerosis in Low- and Middle-Income Countries: A Systematic Review.
    Dahham J; Rizk R; Kremer I; Evers SMAA; Hiligsmann M
    Pharmacoeconomics; 2021 Jul; 39(7):789-807. PubMed ID: 33956330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.